Artificial intelligence applications in prostate cancer.

Journal: Prostate cancer and prostatic diseases
Published Date: Jun 9, 2023

Abstract

Artificial intelligence (AI) applications have enabled remarkable advancements in healthcare delivery. These AI tools are often aimed to improve accuracy and efficiency of histopathology assessment and diagnostic imaging interpretation, risk stratification (i.e., prognostication), and prediction of therapeutic benefit for personalized treatment recommendations. To date, multiple AI algorithms have been explored for prostate cancer to address automation of clinical workflow, integration of data from multiple domains in the decision-making process, and the generation of diagnostic, prognostic, and predictive biomarkers. While many studies remain within the pre-clinical space or lack validation, the last few years have witnessed the emergence of robust AI-based biomarkers validated on thousands of patients, and the prospective deployment of clinically-integrated workflows for automated radiation therapy design. To advance the field forward, multi-institutional and multi-disciplinary collaborations are needed in order to prospectively implement interoperable and accountable AI technology routinely in clinic.

Authors

  • Atallah Baydoun
    Department of Internal Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA; Department of Internal Medicine, Louis Stokes VA Medical Center, Cleveland, OH, USA; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA. Electronic address: atallah.baydoun@case.edu.
  • Angela Y Jia
    Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Nicholas G Zaorsky
    Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Rojano Kashani
    Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Santosh Rao
    Department of Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Jonathan E Shoag
    Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, New York, USA.
  • Randy A Vince
    Department of Urology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Leonardo Kayat Bittencourt
    Department of Radiology, University Hospitals Cleveland Medical Center Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Raed Zuhour
    Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Alex T Price
    Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Theodore H Arsenault
    Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Daniel E Spratt
    Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland.

Keywords

External Resources

Popular Topics
Recent Journals